Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Radioresistance significantly impairs treatment efficacy and prognostic outcomes in head and neck squamous cell carcinoma (HNSCC). This study aimed to identify radiotherapy sensitivity-related genes and construct a prognostic model for HNSCC, incorporating insights from nasopharyngeal carcinoma (NPC) as a related subtype.
Methods: Differentially expressed genes (DEGs) associated with radiotherapy response were identified using the GSE48501 dataset, primarily derived from NPC. Functional annotation was performed via Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. Using the TCGA-HNSC dataset, we developed a prognostic risk model through univariate and LASSO-Cox regression analyses. The model was validated for prognostic accuracy and further analyzed for associations with immune cell infiltration, drug sensitivity, and survival outcomes using CIBERSORT, TIMER, Genomics of Drug Sensitivity in Cancer (GDSC), and nomogram analysis.
Results: We identified 263 DEGs related to radiotherapy sensitivity and developed a robust prognostic model based on 8 hub genes. The model effectively stratified patients into high- and low-risk groups, with superior overall survival (OS) observed in the low-risk group. The Receiver Operating Characteristic (ROC) analysis confirmed high predictive accuracy for 1-, 3-, and 5-year OS. Immune infiltration analysis revealed reduced immune activity in the high-risk group, while drug sensitivity analysis highlighted potential therapeutic strategies. The nomogram further demonstrated excellent predictive performance.
Conclusion: This study bridges insights from NPC-derived DEGs and HNSCC prognostic modeling, emphasizing radiotherapy sensitivity and integrating immune and therapeutic dimensions. The resulting model offers a novel approach to improve prognostic accuracy and guide treatment strategies for HNSCC patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12106292 | PMC |
| http://dx.doi.org/10.1007/s12672-025-02731-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic factors of lenvatinib plus pembrolizumab therapy for advanced or recurrent endometrial cancer: analysis of a multicenter cohort study in Japan.
Int J Clin Oncol
September 2025
Department of Obstetrics and Gynecology, The University of Osaka Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Background: Lenvatinib plus pembrolizumab (LP) therapy has emerged as an effective treatment for patients with advanced or recurrent endometrial cancer. However, limited data are available regarding its outcomes in real-world settings. This study aimed to identify prognostic factors associated with the efficacy of LP therapy.
View Article and Find Full Text PDFPrediction of cognitive decline and Alzheimer's disease conversion by a plasma biomarker panel in non-demented individuals.
Geroscience
September 2025
Department of Biological Sciences, College of Natural Sciences, Kangwon National University, Kangwon, 24341, Republic of Korea.
Alzheimer's disease (AD) represents a growing global health burden, underscoring the urgent need for reliable diagnostic and prognostic biomarkers. Although several disease-modifying treatments have recently become available, their effects remain limited, as they primarily delay rather than halt disease progression. Thus, the early and accurate identification of individuals at elevated risk for conversion to AD dementia is crucial to maximize the effectiveness of these therapies and to facilitate timely intervention strategies.
View Article and Find Full Text PDFCancer-specific mortality in secondary bladder cancer after nephroureterectomy for upper tract urothelial carcinoma.
Urol Oncol
September 2025
Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Objective: To examine differences in cancer-specific mortality (CSM) in nonmetastatic upper tract urothelial carcinoma (UTUC) patients with vs. without secondary bladder cancer (BCa) after radical nephroureterectomy (RNU).
Methods: Within the Surveillance, Epidemiology, and End Results database (SEER 2000-2021), T1-T4N0M0 UTUC patients treated with RNU and diagnosed with secondary BCa were identified.
Neuro-Immuno-Stromal Context in Colorectal Cancer: An Enteric Glial Cell-Driven Prognostic Model via Machine Learning Predicts Survival, Recurrence, and Therapy Response.
Exp Cell Res
September 2025
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Gastrointestinal Cancer Center, Peking University Cancer Hospital and Institute, Beijing, China. Electronic address:
Background: Enteric glial cells (EGCs) have been implicated in colorectal cancer (CRC) progression. This study aimed to develop and validate a prognostic model integrating EGC- and CRC-associated gene expression to predict patient survival, recurrence, metastasis, and therapy response.
Methods: Bulk and single-cell RNA sequencing data were analyzed, and a machine learning-based model was constructed using the RSF random forest algorithm.
MiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trial.
Transl Oncol
September 2025
Université Paris Cité, Thoracic Oncology Department & CIC1425, Hôpital Bichat-Claude Bernard, Assistance Publique Hôpitaux de Paris (AP-HP), Paris, France; U830 INSERM "Cancer, Heterogeneity, Instability, Plasticity, A.R.T group", Curie Institute, Paris, France. Electronic address: gerard.zalcma
We investigated whether angiogenesis-related microRNAs (miRNAs) predict survival in patients with pleural mesothelioma (PM) treated with bevacizumab plus pemetrexed-platinum chemotherapy in the Mesothelioma Avastin Cisplatin Pemetrexed Study ('MAPS', NCT00651456) phase 3 trial phase III trial (NCT00651456). Twelve miRNAs were measured in FFPE samples from 236 of the 448 MAPS trial patients (50.8 %), normalized to RNU48.
View Article and Find Full Text PDF